Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).
Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy.
sac-TMT is an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech.
Read Also: Merck One of Top Large-Cap Biopharma Picks-Analyst
Trial Efficacy And Safety Results
At final analysis, sac-TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.
Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.
However, sac-TMT did not meet its…